CAS 2060571-02-8

GDC-0077

Description:

GDC-0077 is a small molecule inhibitor primarily designed to target the protein kinase AKT, which plays a crucial role in various cellular processes, including metabolism, proliferation, and survival. This compound is part of a class of drugs that aim to disrupt the signaling pathways associated with cancer cell growth and survival, making it a candidate for cancer therapy, particularly in tumors with aberrant AKT signaling. GDC-0077 exhibits selectivity for specific isoforms of AKT, which is important for minimizing off-target effects and enhancing therapeutic efficacy. The compound has undergone various stages of preclinical and clinical development, demonstrating potential in treating certain types of cancers, including breast cancer and other malignancies characterized by mutations in the PI3K/AKT pathway. Its pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion, are critical for determining its suitability for clinical use. As with many investigational drugs, ongoing studies are essential to fully understand its safety profile and therapeutic potential.

Formula: C₁₈H₁₉F₂N₅O₄

Synonyms:

• GDC-0077; RG 6114; RO 7113755
• CPD1573
• GDC-0077
• (2S)-2-[[2-[(4S)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]amino]propanamide
• RO 7113755
• RG 6114
• Propanamide, 2-[[2-[(4S)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]amino]-, (2S)-

Inavolisib

CAS: 2060571-02-8

Inavolisib (GDC-0077) is an orally available selective PI3Kα inhibitor with an IC50 value of 0.038 nM.Cost-effective and quality-assured.

Formula: C₁₈H₁₉F₂N₅O₄

Purity: 97.36% - 99.87%

Color and Shape: Solid

Molecular weight: 407.37

Ref: TM-T15375

Inavolisib

CAS: 2060571-02-8

Inavolisib

Purity: ≥95%

Molecular weight: 407.37g/mol

Ref: 54-BUP12569

Inavolisib

CAS: 2060571-02-8

Formula: C₁₈H₁₉F₂N₅O₄

Molecular weight: 407.38

Ref: 4Z-I-168001

GDC-0077

CAS: 2060571-02-8

GDC-0077 is a small molecule that specifically targets the lipid kinase activity of CDK4/6. It has been shown to have anti-inflammatory effects in animal models of inflammatory diseases, such as arthritis and colitis, by suppressing the expression of inflammatory genes. GDC-0077 has also been shown to be effective in suppressing tumor growth and prolonging survival in animal models of cancer. GDC-0077 inhibits the proliferation of cancer cells by interrupting cell cycle progression at the G2/M checkpoint. The compound is being investigated for its potential as a treatment for cancers with mutations in CDK4 or CDK6, such as breast, prostate, and endometrial cancers.

Formula: C₁₈H₁₉F₂N₅O₄

Purity: Min. 95%

Molecular weight: 407.37 g/mol

Ref: 3D-KHD57102